¼¼°èÀÇ Àü½Å¸¶ÃëÁ¦ ½ÃÀå
General Anesthesia Drugs
»óǰÄÚµå : 1564904
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 193 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,260,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,780,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Àü½Å ¸¶ÃëÁ¦ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 98¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»ó

2023³â 78¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°è Àü½Å ¸¶ÃëÁ¦ ½ÃÀåÀº 2023-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È ¿¬Æò±Õ 3.2% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 98¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÇÁ·ÎÆ÷ÆúÀº CAGR 3.1%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ Á¾·á ½ÃÁ¡¿¡ 25¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼¼º¸Ç÷ç¶õ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 3.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 21¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 4.8%·Î ¼ºÀå Àü¸Á

¹Ì±¹ Àü½Å¸¶ÃëÁ¦ ½ÃÀåÀº 2023³â 21¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö ½ÃÀå ±Ô¸ð°¡ 19¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È 4.8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 2.2%¿Í 2.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ 2.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è Àü½Å¸¶ÃëÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

Àü½Å ¸¶ÃëÁ¦´Â ¿Ö Çö´ëÀÇ ¿Ü°ú ¼ö¼ú°ú ÀÇ·á ½Ã¼ú¿¡ ÇʼöÀûÀΰ¡?

Àü½Å ¸¶ÃëÁ¦´Â Çö´ëÀÇ ¼ö¼ú°ú ÀÇ·á ½Ã¼ú¿¡¼­ ¸Å¿ì Áß¿äÇϸç, ȯÀÚ°¡ ÅëÁõÀ̳ª ºÒÆíÇÔ, ÀÇ½Ä ¾øÀÌ º¹ÀâÇϰí ħ½ÀÀûÀÎ ¼ö¼úÀ» ¹ÞÀ» ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ±×·±µ¥ ¿Ö ¿À´Ã³¯ ÀÌ·¯ÇÑ ¾à¹°ÀÌ ÇʼöÀûÀÎ °ÍÀϱî? Àü½Å¸¶Ãë´Â °¡¿ªÀûÀÎ ÀÇ½Ä »ó½Ç, ÁøÅë, ±ÙÀ° ÀÌ¿Ï, ±â¾ï»ó½Ç »óŸ¦ À¯¹ßÇÏ¿© ȯÀÚ¿¡°Ô °íÅëÀ̳ª ½ÅüÀû ÇØ¸¦ ³¢Ä¡Áö ¾Ê°í º¹ÀâÇÑ ¼ö¼úÀ» ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÏ»óÀûÀÎ ¼ö¼ú¿¡¼­ »ý¸íÀ» ±¸ÇÏ´Â ¼ö¼ú¿¡ À̸£±â±îÁö Àü½Å¸¶Ãë´Â ȯÀÚ°¡ ¼ö¼ú ³»³» ÀǽÄÀÌ ¾ø°í ÅëÁõÀÌ ¾ø´Â »óŸ¦ À¯ÁöÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿© Çö´ë ÀÇÇÐÀÇ ¼º°ø°ú ¾ÈÀü¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¸¶ÃëÁ¦´Â ½ÉÀå ¿ìȸ ¼ö¼ú, Àå±â À̽Ä, Á¤Çü¿Ü°ú ¼ö¼ú°ú °°Àº Å« ¼ö¼úÀ̳ª ´ëÀå ³»½Ã°æ °Ë»ç, »ý°Ë°ú °°ÀÌ È¯ÀÚ°¡ Àå½Ã°£ °¡¸¸È÷ ÀÖ¾î¾ß ÇÏ´Â Áø´ÜÀû ½Ã¼ú µî ´Ù¾çÇÑ ÀÇ·á ÇöÀå¿¡¼­ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¸¶Ãë°ú Àü¹®ÀǴ ȯÀÚÀÇ ³ªÀÌ, üÁß, °Ç°­ »óÅÂ, ¼ö¼ú ³»¿ë µîÀ» °í·ÁÇØ ¾ÈÀüÇϰí È¿°úÀûÀÎ ÁøÁ¤À» À§ÇÑ ¾à¹°ÀÇ ÀûÀýÇÑ ±ÕÇüÀ» À¯ÁöÇϸ鼭 ȯÀÚ °³°³Àο¡ ¸Â´Â Àü½Å¸¶ÃëÁ¦¸¦ Åõ¿©ÇÕ´Ï´Ù. ÀǽÄ, ÅëÁõ ¹× ½Åü ±â´ÉÀ» Á¶ÀýÇÏ´Â ´É·ÂÀº ¼ö¼úÀÇ Á¤È®¼ºÀ» ³ôÀÌ´Â µ¥ ÇʼöÀûÀ̸ç, ÀÇ·á Àü¹®°¡´Â ȯÀÚÀÇ ¿òÁ÷ÀÓÀ̳ª ºÒÆíÇÔ¿¡ ´ëÇØ °ÆÁ¤ÇÏÁö ¾Ê°í ´«¾ÕÀÇ ÀÛ¾÷¿¡ ÀüÀûÀ¸·Î ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº Àü½Å ¸¶ÃëÁ¦ÀÇ ¾ÈÀü¼º°ú Á¤È®¼ºÀ» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº Àü½Å ¸¶ÃëÀÇ ¾ÈÀü¼º, Á¤È®¼º ¹× Àü¹ÝÀûÀÎ °ü¸®¸¦ Å©°Ô Çâ»ó½ÃÄÑ ´õ ³ªÀº ȯÀÚ °á°ú¸¦ º¸ÀåÇÏ°í ¸¶Ãë¿Í °ü·ÃµÈ À§ÇèÀ» ÁÙ¿´½À´Ï´Ù. °¡Àå ¿µÇâ·Â ÀÖ´Â ¹ßÀü Áß Çϳª´Â ¸¶Ãë°ú Àǻ簡 ¼ö¼ú Áß ½É¹Ú¼ö, »ê¼Ò ³óµµ, Ç÷¾Ð, ³ú Ȱµ¿ µî ȯÀÚÀÇ È°·Â ¡Èĸ¦ ¸é¹ÐÈ÷ ÃßÀûÇÒ ¼ö Àִ ÷´Ü ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀ» µµÀÔÇÑ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ½Ç½Ã°£ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀº ȯÀÚÀÇ ¸¶Ãë ¹ÝÀÀ¿¡ ´ëÇÑ Áß¿äÇÑ Çǵå¹éÀ» Á¦°øÇϰí, ÀÇ·áÁøÀÌ ÀÌ»óÀûÀÎ ¸¶Ãë ±íÀ̸¦ À¯ÁöÇϱâ À§ÇØ ½Ç½Ã°£À¸·Î ¾à¹° ¿ë·®À» Á¶Á¤ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÌ ±â¼úÀº ¼ö¼ú Áß ÀÇ½Ä Àå¾Ö ¹× ºÎÀÛ¿ëÀ¸·Î À̾îÁú ¼ö ÀÖ´Â ¸¶Ãë °úºÎÁ·°ú °°Àº ÇÕº´ÁõÀ» ¿¹¹æÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ ¹ßÀüÀº ÁøÁ¤ ¼öÁØÀ» ´õ Àß Á¦¾îÇϰí ȸº¹ ½Ã°£À» ´ÜÃàÇÏ´Â ´Ü½Ã°£ ÀÛ¿ë ¸¶ÃëÁ¦ÀÇ °³¹ßÀÔ´Ï´Ù. ÇÁ·ÎÆ÷Æú, ¼¼º¸Ç÷ç¶õ, µ¥½ºÇ÷ç¶õ°ú °°Àº ÃֽЏ¶ÃëÁ¦´Â ¸¶ÃëÀÇ µµÀÔ°ú ÇØÁ¦¸¦ ºü¸£°Ô ÇÒ ¼ö Àֱ⠶§¹®¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸¶ÃëÁ¦´Â ¸¶Ãë ½Ã°£À» º¸´Ù Á¤È®ÇÏ°Ô Á¦¾îÇÒ ¼ö ÀÖ¾î ȸº¹ÀÌ ±æ¾îÁö°Å³ª ¸Þ½º²¨¿ò, ±¸Åä, ÀÎÁö Àå¾Ö¿Í °°Àº ¼ö¼ú ÈÄ ÇÕº´Áõ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ȸº¹ ½Ã°£ ´ÜÃàÀº ȯÀÚ°¡ ¼ö¼ú ÈÄ ½Å¼ÓÇÏ°Ô ÀǽÄÀ» ȸº¹ÇÏ°í ¾ÈÁ¤À» µÇã¾Æ¾ß ÇÏ´Â ¿Ü·¡ ¼ö¼ú¿¡¼­ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù.

¾à¸®À¯ÀüüÇÐ(À¯ÀüÀÚ°¡ ¾à¹°¿¡ ´ëÇÑ ¹ÝÀÀ¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡´ÂÁö ¿¬±¸ÇÏ´Â Çй®)ÀÇ ºÎ»óµµ ¸¶ÃëÀÇ ÁøÈ­¿¡ ÇѸòÀ» Çϰí ÀÖ½À´Ï´Ù. ¸¶Ãë°ú ÀÇ»ç´Â ÀÌÁ¦ À¯ÀüÀÚ µ¥ÀÌÅ͸¦ ÅëÇØ ȯÀÚ°¡ ƯÁ¤ ¸¶ÃëÁ¦¸¦ ¾î¶»°Ô ´ë»çÇÒÁö¸¦ ¿¹ÃøÇÒ ¼ö ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ ºÎÀÛ¿ëÀÇ °¡´É¼ºÀ» ÁÙÀ̰í, °¢ ȯÀÚ°¡ ÀÚ½ÅÀÇ À¯ÀüÀû üÁú¿¡ ¸Â´Â °¡Àå È¿°úÀûÀÌ°í ¾ÈÀüÇÑ ¸¶Ãë °èȹÀ» ¼¼¿ï ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, Ç¥Àû Á¦¾î ÁÖÀÔ(TCI) ÆßÇÁ¿Í °°Àº ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀüÀº ¸¶ÃëÁ¦ Åõ¿© ¼Óµµ¸¦ º¸´Ù Á¤¹ÐÇÏ°Ô Á¦¾îÇϰí Á¤È®µµ¸¦ Çâ»ó½ÃÄÑ °ú´Ù Åõ¿© ¹× ÇÕº´Áõ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

¸ð´ÏÅ͸µ, ¾à¹° ó¹æ, À¯ÀüÀû ÅëÂû·Â, Àü´Þ ½Ã½ºÅÛÀÇ ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î Àü½Å¸¶ÃëÀÇ Åõ¿©´Â ´õ¿í ¾ÈÀüÇϰí È¿À²ÀûÀÌ¸ç °³º° ȯÀÚÀÇ ¿ä±¸¿¡ ´õ Àß ¸ÂÃâ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

Àü½Å ¸¶ÃëÁ¦°¡ ¼ö¼ú Áß È¯ÀÚÀÇ ¾ÈÀü°ú Æí¾ÈÇÔ¿¡ Áß¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Àü½Å ¸¶Ãë´Â ¿ÏÀüÇÑ ÁøÅë, ÀÇ½Ä ¼Ò½Ç ¹× ±ÙÀ° ÀÌ¿ÏÀ» Á¦°øÇϱ⠶§¹®¿¡ ¼ö¼ú Áß È¯ÀÚÀÇ ¾ÈÀü°ú Æí¾ÈÇÔÀ» º¸ÀåÇÏ´Â ±âº»ÀÔ´Ï´Ù. Àü½Å ¸¶ÃëÀÇ °¡Àå Áß¿äÇÑ ¿ªÇÒ Áß Çϳª´Â ħ½ÀÀû ½Ã¼ú Áß ÅëÁõÀ» ¿¹¹æÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°ÀÌ ¾øÀ¸¸é ȯÀÚ´Â °ßµô ¼ö ¾ø´Â ÅëÁõÀ» °æÇèÇÏ°Ô µÇ°í, ÀÌ´Â ¼ö¼ú Áß ¿Ü»ó, ¼îÅ© ¹× ½É°¢ÇÑ »ý¸®Àû ½ºÆ®·¹½º·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. Àü½Å¸¶ÃëÁ¦´Â ÁßÃ߽Űæ°è°¡ ÅëÁõ ½ÅÈ£¸¦ ó¸®ÇÏ´Â ´É·ÂÀ» ¾ïÁ¦ÇÏ¿© ÅëÁõ ÀνÄÀ» Â÷´ÜÇÏ¿© ȯÀÚ°¡ ¼ö¼ú Áß ÅëÁõÀ» ´À³¢Áö ¸øÇϵµ·Ï ÇÕ´Ï´Ù.

¶ÇÇÑ Àü½Å¸¶Ãë´Â ÀǽÄÀÌ ¾ø´Â »óŸ¦ À¯µµÇϱ⠶§¹®¿¡ ¿Ü°úÀÇ»ç´Â ȯÀÚ¿¡°Ô °íÅëÀ» ÁÖÁö ¾Ê°í º¹ÀâÇϰí Àå½Ã°£ÀÇ ¼ö¼úÀ» ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü½Å ¸¶Ãë¿¡ »ç¿ëµÇ´Â ¾à¹°¿¡´Â ±ÙÀÌ¿ÏÁ¦°¡ Æ÷ÇԵǾî ÀÖÀ¸¸ç, ÀÌ´Â Á¤Çü¿Ü°ú ¼ö¼úÀ̳ª ½Å°æ¿Ü°ú ¼ö¼ú°ú °°ÀÌ Á¤È®¼º°ú ºÎµ¿¼ºÀÌ ¿ä±¸µÇ´Â ¼ö¼ú¿¡¼­ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. ¸¶ÃëÁ¦´Â ȯÀÚÀÇ ±ÙÀ°À» À̿ϽÃÄÑ ¿Ü°ú ÀÇ»çÀÇ ÀÛ¾÷À» ¹æÇØÇÏ´Â ºñÀÚ¹ßÀû ÀÎ ¿òÁ÷ÀÓÀ» ¹æÁöÇÏ¿© ¼ö¼úÀÇ ¾ÈÀü¼º°ú ¼º°ø·üÀ» ³ôÀÔ´Ï´Ù.

Àü½Å¸¶Ãë´Â ¼ö¼ú ÈÄ °ü¸®µµ °³¼±µË´Ï´Ù. ÀϹÝÀûÀ¸·Î ¸¶ÃëÁ¦¿¡´Â ±â¾ï»ó½ÇÁõÀ» À¯¹ßÇÏ´Â ¾à¹°ÀÌ Æ÷ÇԵǾî Àֱ⠶§¹®¿¡ ȯÀÚ´Â ¼ö¼ú°ú ±×¿¡ µû¸¥ ºÒÆíÇÔ¿¡ ´ëÇÑ ±â¾ïÀÌ ¾ø½À´Ï´Ù. ÀÌ·¸°Ô ¼ö¼ú Áß ÀǽÄÀ» ÀÒ°Ô µÇ¸é ħ½ÀÀû ½Ã¼ú·Î ÀÎÇÑ ½É¸®Àû ¿Ü»ó À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àü½Å¸¶Ãë´Â ¿ÏÀüÇÑ ÁøÁ¤À» º¸ÀåÇÏ¿© Å« ¼ö¼ú Áß ¼Õ»óµÉ ¼ö ÀÖ´Â ½ÉÇ÷°ü°è, È£Èí±â µî ½Åü¿¡ °¡ÇØÁö´Â »ý¸®Àû ½ºÆ®·¹½º¸¦ ÁÙ¿©ÁÝ´Ï´Ù. ÀÌ·¯ÇÑ ÅëÁ¦µÈ ȯ°æÀº ƯÈ÷ Áöº´ÀÌ Àְųª °íÀ§Çè ¼ö¼úÀ» ¹Þ´Â ȯÀÚÀÇ ¾ÈÀü¿¡ ÇʼöÀûÀÔ´Ï´Ù.

ÀüüÀûÀ¸·Î Àü½Å ¸¶ÃëÀÇ ¿ªÇÒÀº ȯÀÚ°¡ Æí¾ÈÇϰí ÅëÁõÀ» ´À³¢Áö ¾Êµµ·Ï ÇÒ»Ó¸¸ ¾Æ´Ï¶ó ¼ö¼úÀ» ¾ÈÀüÇϰí È¿°úÀûÀ¸·Î ¼öÇà ÇÒ ¼öÀÖ´Â ¾ÈÁ¤µÈ »ý¸®Àû ȯ°æÀ» Á¶¼ºÇÏ´Â °ÍÀÔ´Ï´Ù. Àü½Å ¸¶Ãë´Â Çö´ë ¿Ü°ú ÀÇ·áÀÇ Çʼö ¿ä¼Ò·Î, ´õ ³ôÀº Á¤È®µµ, ´õ ÀûÀº ÇÕº´Áõ ¹× ´õ ³ªÀº ȯÀÚ °á°ú¸¦ °¡´ÉÇϰÔÇÕ´Ï´Ù.

Àü½Å ¸¶ÃëÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Àü½Å ¸¶ÃëÁ¦ ½ÃÀåÀº ¼ö¼ú °Ç¼ö Áõ°¡, ¾à¹° Á¦Á¦ÀÇ ¹ßÀü, ȯÀÚÀÇ ¾ÈÀü°ú ȸº¹¿¡ ´ëÇÑ °ü½É Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ù°, ¼±ÅÃÀû ¼ö¼ú, ÀÀ±Þ ¼ö¼ú ¹× ¿Ü·¡ ¼ö¼úÀ» Æ÷ÇÔÇÑ Àü ¼¼°è ¿Ü°ú ¼ö¼ú Áõ°¡´Â ¸¶ÃëÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ƯÈ÷ °³¹ßµµ»ó±¹¿¡¼­ ÀÇ·á ÀÎÇÁ¶ó°¡ °³¼±µÊ¿¡ µû¶ó ¿Ü°úÀû Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ¾î ¸¶Ãë ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àα¸ °í·ÉÈ­¿Í ½ÉÇ÷°ü Áúȯ, ¾Ï, Á¤Çü¿Ü°ú Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¼ö¼ú °Ç¼ö Áõ°¡¿¡ ±â¿©ÇÏ¿© Àü½Å ¸¶ÃëÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

µÑ°, ¸¶ÃëÁ¦ÀÇ ¹ßÀüÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÇÁ·ÎÆ÷Æú, ¼¼º¸Ç÷ç¶õ, ·¹¹ÌÆæÅ¸´Ò°ú °°Àº »õ·Î¿î ¸¶ÃëÁ¦ÀÇ °³¹ß·Î Àü½Å ¸¶Ãë°¡ ´õ¿í ¾ÈÀüÇϰí È¿À²ÀûÀ̸ç ȯÀÚÀÇ ³»¾à¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº ºü¸¥ ¸¶Ãë ½ÃÀÛ°ú ȸº¹, ºÎÀÛ¿ë °¨¼Ò, ÁøÁ¤ ±íÀÌ Á¶ÀýÀÌ °¡´ÉÇÏ¿© ´Ù¾çÇÑ ¼ö¼ú¿¡ ÀÌ»óÀûÀÔ´Ï´Ù. ¶ÇÇÑ, ªÀº ½Ã°£¿¡ ÀÛ¿ëÇÏ´Â ¸¶ÃëÁ¦¸¦ ÇÊ¿ä·Î ÇÏ´Â ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ ȯÀÚÀÇ ºü¸¥ ȸº¹°ú ÀÔ¿ø ±â°£À» ´ÜÃàÇÒ ¼ö Àִ ÷´Ü Àü½Å¸¶ÃëÁ¦¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¼Â°, ȯÀÚ ¾ÈÀü°ú ȸº¹ ÇÁ·ÎÅäÄÝ °­È­¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ Àü½Å¸¶ÃëÁ¦ ½ÃÀåÀÌ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀº ¼ö¼ú ÈÄ ÇÕº´ÁõÀ» ÁÙÀ̰í ȯÀÚ ¸ÂÃãÇü ¸¶Ãë ¿ä¹ýÀ» »ç¿ëÇÏ¿© ¼ö¼ú °á°ú¸¦ °³¼±ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ¼ö¼ú ÈÄ È¸º¹ ÃËÁø(ERAS: Enhanced Recovery After Surgery) ÇÁ·ÎÅäÄÝÀº ¼ö¼ú·Î ÀÎÇÑ ½ÅüÀû ½ºÆ®·¹½º¸¦ ÃÖ¼ÒÈ­ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϸç, ȸº¹ ¼Óµµ¸¦ ³ôÀÌ°í ¼ö¼ú ÈÄ ¸Þ½º²¨¿ò, ±¸Åä, ÀÎÁö ±â´É Àå¾ÖÀÇ À§ÇèÀ» °¨¼Ò½ÃŰ´Â ÃֽЏ¶ÃëÁ¦¸¦ »ç¿ëÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. µµÀԵǰí ÀÖ½À´Ï´Ù. º´¿ø°ú ¼ö¼ú¼¾ÅͰ¡ ȯÀÚ Ä¡·áÀÇ ¸ð¹ü »ç·Ê¸¦ äÅÃÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ Ã·´Ü ¸¶Ãë ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ¿Ü·¡ ȯÀÚ ¹× ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)ÀÇ È®ÀåÀº Àü½Å ¸¶ÃëÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ȯÀÚ°¡ ´çÀÏ Åð¿øÇÏ´Â ¿Ü·¡ ¼ö¼úÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ȸº¹ÀÌ ºü¸£°í ºÎÀÛ¿ëÀÌ ÀûÀº ¸¶ÃëÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹é³»Àå ¼ö¼ú, ³»½Ã°æ ¼ö¼ú, ¼ºÇü ¼ö¼ú°ú °°Àº ¿Ü·¡ ¼ö¼ú¿¡¼­´Â ȯÀÚ°¡ ÀǽÄÀ» »¡¸® ȸº¹Çϰí Àå±â ÀÔ¿ø ¾øÀÌ È¸º¹ÇÒ ¼ö ÀÖ´Â ´Ü½Ã°£ ÀÛ¿ë ¸¶ÃëÁ¦°¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

¸¶Áö¸·À¸·Î, ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í Ç¥Àû Á¦¾î ÁÖÀÔ(TCI) ÀåÄ¡ ¹× ÷´Ü ¸ð´ÏÅ͸µ ±â¼ú°ú °°Àº ¸¶Ãë Åõ¿© ½Ã½ºÅÛÀÇ ±â¼ú ¹ßÀüµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº º¸´Ù ¾ÈÀüÇϰí Á¤È®ÇÑ ¸¶ÃëÁ¦ Åõ¿©¸¦ º¸ÀåÇϰí ȯÀÚÀÇ ¾ÈÀüÀ» ´õ¿í Çâ»ó½ÃÄÑ º¸´Ù »õ·Ó°í È¿°úÀûÀÎ ¸¶ÃëÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

°á·ÐÀûÀ¸·Î, Àü½Å¸¶ÃëÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ¼ö¼ú °Ç¼ö Áõ°¡, ¸¶ÃëÁ¦ °³¹ßÀÇ ¹ßÀü, ȯÀÚ ¾ÈÀü¿¡ ´ëÇÑ °ü½É Áõ°¡, ¿Ü·¡ ¼ö¼ú Ä¡·áÀÇ È®´ë¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü°¡ ¼ö¼ú °á°ú °³¼±°ú ȸº¹ ½Ã°£ ´ÜÃàÀ» ÃÖ¿ì¼± °úÁ¦·Î »ïÀ¸¸é¼­ °íǰÁú Àü½Å ¸¶ÃëÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ ÇʼöÀûÀÎ ½ÃÀåÀº Áö¼ÓÀûÀ¸·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(ÁÖ¸ñ¹Þ´Â 43°³ ±â¾÷)

  • Abbott Laboratories
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Eisai Co.
  • F. Hoffmann-La Roche AG
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Hospira, Inc.
  • Novartis AG
  • Pfizer, Inc.

    ¸ñÂ÷

    Á¦1Àå Á¶»ç ¹æ¹ý

    Á¦2Àå ÁÖ¿ä ¿ä¾à

    • ½ÃÀå °³¿ä
    • ÁÖ¿ä ±â¾÷
    • ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ
    • ¼¼°è ½ÃÀå Àü¸Á

    Á¦3Àå ½ÃÀå ºÐ¼®

    • ¹Ì±¹
    • ij³ª´Ù
    • ÀϺ»
    • Áß±¹
    • À¯·´
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ¿µ±¹
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • È£ÁÖ
    • Àεµ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿
    • À̶õ
    • À̽º¶ó¿¤
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ±âŸ Áßµ¿
    • ¾ÆÇÁ¸®Ä«

    Á¦4Àå °æÀï

    LSH
  • ¿µ¹® ¸ñÂ÷

    ¿µ¹®¸ñÂ÷

    Global General Anesthesia Drugs Market to Reach US$9.8 Billion by 2030

    The global market for General Anesthesia Drugs estimated at US$7.8 Billion in the year 2023, is expected to reach US$9.8 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2023-2030. Propofol, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the Sevoflurane segment is estimated at 3.2% CAGR over the analysis period.

    The U.S. Market is Estimated at US$2.1 Billion While China is Forecast to Grow at 4.8% CAGR

    The General Anesthesia Drugs market in the U.S. is estimated at US$2.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

    Global General Anesthesia Drugs Market - Key Trends and Drivers Summarized

    Why Are General Anesthesia Drugs Essential in Modern Surgery and Medical Procedures?

    General anesthesia drugs are critical in modern surgery and medical procedures, allowing patients to undergo complex and often invasive operations without pain, discomfort, or awareness. But why are these drugs so essential today? General anesthesia induces a reversible state of unconsciousness, pain relief, muscle relaxation, and amnesia, making it possible for surgeons to perform intricate procedures without causing distress or physical harm to the patient. From routine surgeries to life-saving operations, general anesthesia ensures that patients remain unaware and pain-free throughout the procedure, contributing to the success and safety of modern medicine.

    These drugs are used in a wide variety of medical settings, including major surgeries like heart bypass, organ transplants, and orthopedic operations, as well as in diagnostic procedures such as colonoscopies or biopsies that require patients to remain still for extended periods. Anesthesiologists tailor the administration of general anesthesia to each patient, taking into account factors like age, weight, health conditions, and the nature of the surgery to ensure the correct balance of drugs for safe and effective sedation. The ability to control consciousness, pain, and bodily functions is vital for surgical precision, allowing healthcare professionals to focus entirely on the task at hand without concerns over patient movement or discomfort.

    How Are Technological Advancements Improving the Safety and Precision of General Anesthesia Drugs?

    Technological advancements are significantly enhancing the safety, precision, and overall administration of general anesthesia drugs, ensuring better patient outcomes and reducing the risks associated with anesthesia. One of the most impactful developments is the introduction of advanced monitoring systems that allow anesthesiologists to closely track a patient’s vital signs, including heart rate, oxygen levels, blood pressure, and brain activity during surgery. These real-time monitoring systems provide critical feedback on how the patient is responding to the anesthesia, enabling healthcare providers to adjust drug dosages in real time to maintain the ideal depth of anesthesia. This technology helps prevent complications like under- or over-sedation, which can lead to awareness during surgery or adverse side effects.

    Another important advancement is the development of shorter-acting anesthetic agents that offer greater control over sedation levels and quicker recovery times. Modern anesthetics such as propofol, sevoflurane, and desflurane have become widely used because they allow for rapid induction and emergence from anesthesia. These agents provide greater precision in controlling the duration of anesthesia, reducing the risks of prolonged recovery and post-operative complications like nausea, vomiting, or cognitive impairment. Faster recovery times are especially beneficial in outpatient surgeries, where patients need to regain consciousness and stability quickly after a procedure.

    The rise of pharmacogenomics—the study of how genes affect a person’s response to drugs—also plays a role in the evolution of anesthesia. Anesthesiologists can now use genetic data to predict how a patient will metabolize specific anesthesia drugs, allowing for more personalized dosing strategies. This reduces the likelihood of adverse reactions and ensures that each patient receives the most effective and safest anesthetic plan tailored to their unique genetic makeup. Additionally, advancements in drug delivery systems, such as target-controlled infusion (TCI) pumps, offer more precise control over the rate at which anesthesia drugs are administered, improving accuracy and reducing the risk of overdose or complications.

    With these advancements in monitoring, drug formulations, genetic insight, and delivery systems, the administration of general anesthesia has become safer, more efficient, and better tailored to the needs of individual patients, greatly improving the overall quality of care.

    Why Are General Anesthesia Drugs Crucial for Patient Safety and Comfort During Surgery?

    General anesthesia drugs are fundamental to ensuring patient safety and comfort during surgery, as they provide complete pain relief, unconsciousness, and muscle relaxation. One of the most important roles of general anesthesia is to prevent pain during invasive procedures. Without these drugs, patients would experience unbearable pain, which could lead to trauma, shock, and significant physiological stress during surgery. General anesthetics block the perception of pain by inhibiting the central nervous system’s ability to process pain signals, ensuring that patients remain pain-free throughout the procedure.

    Additionally, general anesthesia induces a state of unconsciousness, allowing surgeons to perform complex and lengthy surgeries without causing distress to the patient. The drugs used in general anesthesia also include muscle relaxants, which are particularly important in surgeries requiring precision and immobility, such as orthopedic or neurosurgical procedures. By relaxing the patient’s muscles, anesthetics prevent involuntary movements that could interfere with the surgeon’s work, enhancing the safety and success of the operation.

    Post-operative care is also improved by general anesthesia, as the drugs typically include agents that cause amnesia, meaning patients have no recollection of the surgery or the discomfort that might have been involved. This lack of awareness during surgery helps reduce the risk of psychological trauma associated with invasive procedures. Moreover, by ensuring complete sedation, general anesthesia reduces the physiological stress on the body, including the cardiovascular and respiratory systems, which could otherwise be compromised during major surgery. This controlled environment is essential for patient safety, especially for those with pre-existing medical conditions or undergoing high-risk surgeries.

    Overall, the role of general anesthesia is not only to ensure that patients are comfortable and pain-free but also to create a stable physiological environment where the surgery can be performed safely and effectively. It is a vital component of modern surgical care, allowing for greater precision, fewer complications, and better patient outcomes.

    What Factors Are Driving the Growth of the General Anesthesia Drugs Market?

    The general anesthesia drugs market is experiencing significant growth, driven by several key factors, including the rising number of surgical procedures, advancements in drug formulations, and an increasing focus on patient safety and recovery. First, the global rise in surgical procedures, including elective, emergency, and outpatient surgeries, is a major driver of the anesthesia drugs market. As healthcare infrastructure improves, particularly in developing regions, access to surgical care is expanding, leading to an increased demand for anesthesia services. Additionally, the aging population and higher incidence of chronic diseases such as cardiovascular issues, cancer, and orthopedic problems are contributing to the growth of surgeries, further boosting the need for general anesthesia drugs.

    Second, advancements in anesthetic drug formulations are driving market growth. The development of newer anesthetic agents, such as propofol, sevoflurane, and remifentanil, has made general anesthesia safer, more efficient, and better tolerated by patients. These drugs offer rapid onset and recovery, reduced side effects, and better control over sedation depth, making them ideal for a wide range of surgical procedures. The increasing preference for minimally invasive surgeries, which require shorter-acting anesthetics, is also contributing to the demand for advanced general anesthesia drugs that allow for quicker patient recovery and shorter hospital stays.

    Third, the growing emphasis on patient safety and enhanced recovery protocols is boosting the market for general anesthesia drugs. Healthcare providers are focusing on reducing post-operative complications and improving patient outcomes through the use of tailored anesthesia regimens. Enhanced Recovery After Surgery (ERAS) protocols, which aim to minimize the physical stress of surgery, often incorporate modern anesthetic agents that facilitate quicker recovery and reduce the risk of post-operative nausea, vomiting, and cognitive dysfunction. The demand for these advanced anesthesia solutions is driving market growth as hospitals and surgical centers adopt best practices in patient care.

    Additionally, the expansion of outpatient and ambulatory surgery centers is fueling the demand for general anesthesia drugs. As more surgeries shift to outpatient settings, where patients are discharged the same day, there is a growing need for anesthesia drugs that offer rapid recovery times and minimal side effects. Outpatient procedures such as cataract surgeries, endoscopies, and cosmetic surgeries rely on short-acting anesthetics that allow patients to regain consciousness quickly and recover without the need for extended hospitalization.

    Lastly, rising healthcare spending and technological advancements in anesthesia delivery systems, such as target-controlled infusion (TCI) devices and advanced monitoring technologies, are also contributing to market growth. These innovations ensure safer, more precise administration of anesthesia drugs, further enhancing patient safety and driving demand for newer, more effective anesthetic agents.

    In conclusion, the growth of the general anesthesia drugs market is driven by the increasing number of surgeries, advancements in anesthetic drug formulations, a focus on patient safety, and the expansion of outpatient surgical care. As healthcare providers continue to prioritize improved surgical outcomes and faster recovery times, the demand for high-quality general anesthesia drugs is expected to rise, ensuring the continued expansion of this essential market.

    Select Competitors (Total 43 Featured) -

    TABLE OF CONTENTS

    I. METHODOLOGY

    II. EXECUTIVE SUMMARY

    III. MARKET ANALYSIS

    IV. COMPETITION

    (ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
    ¨Ï Copyright Global Information, Inc. All rights reserved.
    PC¹öÀü º¸±â